Pulmonary Cell News 7.17 May 3, 2018 | |
| |
TOP STORYResearchers reported the evidence of miR-483-3p silencing and epithelial-to-mesenchymal transition (EMT) phenotype in both in vitro and in vivo epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) models with acquired resistance to gefitinib. [Oncogene] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)TAT-TVTSP was efficiently delivered to bronchial epithelial cells and significantly reduced Dermatophagoides farinae 2 (Der f 2)-induced phospholipase D activation and interleukin 13 production. [Exp Mol Med] Full Article RNA-Sequencing Reveals Long-Term Effects of Silver Nanoparticles on Human Lung Cells Scientists explored the effects of silver nanoparticles (AgNPs) following repeated low-dose, long-term exposure of human bronchial epithelial cells. To this end, the human BEAS-2B cell line was exposed to 1 µg/mL AgNPs for six weeks followed by RNA-sequencing as well as genome-wide DNA methylation analysis. [Sci Rep] Full Article The CF Canada-Sick Kids Program in Individual CF Therapy is generating a “first of its kind”, comprehensive resource containing patient-specific cell cultures and data from 100 CF individuals that will enable modeling of therapeutic responses. [J Cyst Fibrosis] Full Article LUNG CANCERHOXA4 overexpression in lung cancer cell lines suppressed cell proliferation, migration, and invasion. HOXA4 decreased the protein expression levels of β-catenin, Cyclin D1, c-Myc and Survivin, indicating the inhibition of Wnt signaling. [Cell Death Dis] Full Article Researchers identified and characterized a novel microRNA, hsa-miR-12528, in A549 cells. The miR-12528 expression was aberrantly downregulated in cancer cell lines and in the patient tissues derived from human non-small cell lung cancer. [Cell Death Dis] Full Article Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer Investigators assessed the impact of two high-linear energy transfer (LET) ions 56Fe and 28Si, and low-LET X rays on genome-wide methylation patterns in human bronchial epithelial cells. [Sci Rep] Full Article Upregulation of SALL4 by EGFR Activation Regulates the Stemness of CD44-Positive Lung Cancer The knockdown of Sal-like protein 4 (SALL4) expression suppressed spheroid formation and the expression of lung cancer stem cell marker CD44. The knockdown of SALL4 expression suppressed the migration, invasion, and metastasis of the lung cancer cells and significantly increase the sensitivity of EGFR mutated cells to Erlotinib. [Oncogenesis] Full Article The authors demonstrated that elevated expression of dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000 (DARPP-32), and its truncated splice variant t-DARPP promote lung tumor growth, while abrogation of DARPP-32 expression in human non-small-cell lung cancer cells reduces tumor growth in orthotopic mouse models. [Commun Biol] Full Article | |
| |
REVIEWSThe authors systematically summarize the recent advance of miRNAs in the pathology of idiopathic pulmonary fibrosis, highlighting the new research progress and their pathophysiological implication. [Exp Lung Res] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSBristol-Myers Squibb Company announced that the European Medicines Agency validated a type II variation application for the Opdivo plus Yervoy combination for treatment in adult patients with first-line metastatic NSCLC who have tumor mutational burden ≥10 mutations/megabase. [Bristol-Myers Squibb Company] Press Release MD Anderson, Spectrum Pharmaceuticals Complete Poziotinib Licensing Deal The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by MD Anderson researchers about the company’s drug poziotinib, a targeted therapy for lung cancer. [The University of Texas MD Anderson Cancer Center] Press Release | |
| |
POLICY NEWSNature Announces New Editor-in-Chief Nature has named Magdalena Skipper as its new editor-in-chief. She is the first woman to hold the post. Skipper, who is currently editor-in-chief of the open-access journal Nature Communications, will become the eighth editor of Nature. [Nature News] Editorial Big UK Science Funder Says Report Harassment or Risk Losing Funding One of the world’s largest research-funding charities is cracking down on harassment and bullying. Scientists who have been sanctioned by their institutions could lose out on funding from the Wellcome Trust, under rules announced. [Nature News] Editorial Nature Journals Formalize Ethical Standards for Human Embryo and Stem-Cell Research Nature journals encourage stem-cell scientists to embrace guidelines agreed in 2016 by the International Society for Stem Cell Research as they design, execute and report their research. [Nature News] Editorial Accused Cancer Scientist Resigns as Editor of Prestigious Journal Inder Verma, the prominent cancer scientist and geneticist who has been accused of sexual harassment by several women, resigned yesterday as editor-in-chief of the Proceedings of the National Academy of Sciences, a prestigious academic journal. [ScienceInsider] Editorial
| |
EVENTSNEW Federation of American Societies for Experimental Biology (FASEB): Cross-Translational Research in Fibrosis across Organs Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Research Scientist – Gene Therapy (University of Oxford) Research Technologist – Pulmonary (STEMCELL Technologies Inc.) Postdoctoral Fellow Position – Lung Injury and Repair (University of Kentucky) Postdoctoral Fellow – Lung and Vascular Biology (Northwestern University) Postdoctoral Scholar – Lung Cancer (University of California, San Francisco) Postdoctoral Position – Cell and Molecular Biology (Helmholtz Zentrum München) Postdoctoral Position – Cancer, Immunotherapy, and Fibrosis (University of Alabama at Birmingham) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|